Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Finished Goods: 2023-2025

Historic Finished Goods for Krystal Biotech (KRYS) over the last 2 years, with Sep 2025 value amounting to $7.3 million.

  • Krystal Biotech's Finished Goods rose 126.57% to $7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 million, marking a year-over-year increase of 126.57%. This contributed to the annual value of $2.1 million for FY2024, which is 239.07% up from last year.
  • Latest data reveals that Krystal Biotech reported Finished Goods of $7.3 million as of Q3 2025, which was up 327.07% from $1.7 million recorded in Q2 2025.
  • In the past 5 years, Krystal Biotech's Finished Goods ranged from a high of $7.3 million in Q3 2025 and a low of $161,000 during Q1 2024.
  • Its 3-year average for Finished Goods is $2.8 million, with a median of $1.9 million in 2024.
  • Data for Krystal Biotech's Finished Goods shows a peak YoY soared of 3,563.35% (in 2025) over the last 5 years.
  • Quarterly analysis of 3 years shows Krystal Biotech's Finished Goods stood at $627,000 in 2023, then surged by 239.07% to $2.1 million in 2024, then skyrocketed by 126.57% to $7.3 million in 2025.
  • Its last three reported values are $7.3 million in Q3 2025, $1.7 million for Q2 2025, and $5.9 million during Q1 2025.